Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing global COVID-19 pandemic since 2019 has led to increasing amount of research to study how to do fast screening and diagnosis to efficiently detect COVID-19 positive cases, and how to prevent spreading of the virus. Our research objective was to study whether SARS-CoV-2 could be detected from routine nasopharyngeal swab samples by using attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy coupled with partial least squares discriminant analysis (PLS-DA). The advantage of ATR-FTIR is that measurements can be conducted without any sample preparation and no reagents are needed. Our study included 558 positive and 558 negative samples collected from Northern Finland. Overall, we found moderate diagnostic performance for ATR-FTIR when polymerase chain reaction (PCR) was used as the gold standard: the average area under the receiver operating characteristics curve (AUROC) was 0.67-0.68 (min. 0.65, max. 0.69) with 20, 10 and 5 k-fold cross validations. Mean accuracy, sensitivity and specificity was 0.62-0.63 (min. 0.60, max. 0.65), 0.61 (min. 0.58, max. 0.65) and 0.64 (min. 0.59, max. 0.67) with 20, 10 and 5 k-fold cross validations. As a conclusion, our study with relatively large sample set clearly indicate that measured ATR-FTIR spectrum contains specific information for SARS-CoV-2 infection (P<0.001 in label permutation test). However, the diagnostic performance of ATR-FTIR remained only moderate, potentially due to low concentration of viral particles in the transport medium. Further studies are needed before ATR-FTIR can be recommended for fast screening of SARS-CoV-2 from routine nasopharyngeal swab samples.
Importance Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy coupled with machine learning-based analysis was applied to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from nasopharyngeal swab samples originally collected and processed for polymerase chain reaction (PCR) analysis. Even though our results showed moderate performance, we think that our carefully designed and conducted work is valuable in the field of SARS-CoV-2 diagnostics as there were as many as 1116 nasopharyngeal swab samples (558 negative and 558 positive) collected from individual patients in a real clinical setting. The Real clinical setting refers to the fact that the nasopharyngeal swab samples were collected from people with symptoms typical for COVID-19 or asymptomatic individuals exposed to SARS-CoV-2. The presented technique could be relatively easy to use for point-of-care testing, as ATR-FTIR can be performed with a portable machine without sample preparation and machine learning-based model could give a result immediately after ATR-FTIR measurement.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by European Regional Development Fund (ERDF) (funding number A76179).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical permissions were obtained both locally from the Ethical Committee of North Ostrobothnia's Hospital District as well as nationally from the Finnish Medicines Agency (www.fimea.fi, permission identifier: FIMEA/2021/003461).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
lassi.rieppo{at}oulu.fi
tuija.mannisto{at}nordlab.fi
mikko.sillanpaa{at}oulu.fi
vesa.mantynen{at}nordlab.fi
simo.saarakkala{at}oulu.fi
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos